Mednet Logo

How will you use tocilizumab in the treatment algorithm for SSc-ILD, given its recent FDA approval?

1 Answer
Mednet Member
Mednet MemberInvited Expert
Rheumatology · Harvard Medical School
Answered on

I am excited that we finally have evidence for an effective therapy to treat SSc- ILD. Scleroderma is among the most challenging diseases facing the rheumatologist and over the years we have failed in our efforts to identify potentially effective treatment options for patients, especially those with...

Join for free or sign in to see the full answer